Read 'The Little Book That Still Beats the Market' to explore Morningstar analysts’ industry insights.

Labor carries no inherent hierarchy, yet industries are clearly stratified. Some industries generate profits effortlessly; others demand hard work for modest returns; and still others yield neither ease nor profit. Which industries merit long-term investment? In the second half of 'The Little Book That Still Beats the Market', Pat Dorsey—senior equity analyst at Morningstar, the globally respected rating agency—collaborated with over 30 industry analysts to conduct an in-depth examination of investment opportunities across thirteen sectors, including healthcare, consumer staples, and banking. (For the first half, see: 'The Little Book That Still Beats the Market'.) The industries analyzed in the book pertain to the U.S. stock market, grounded in a mature economy and well-developed capital markets—precisely the developmental trajectory many of our own industries are following. When selecting individual stocks or sector-specific funds, this book offers valuable background reading. Given differences between China and the U.S., certain industries may diverge significantly—requiring careful discernment on our part. Yet the author’s analytical framework—centered on business fundamentals and sustainable competitive advantages—remains highly instructive. In the author’s view, industries fall into two broad categories: First, those naturally conducive to sustaining competitive advantages—where quality companies can be bought at a 'modest discount'; examples include pharmaceuticals and medical devices within healthcare, consumer staples, technology-based business services, and leading banks. Second, those where durable competitive advantages are harder to achieve—requiring a 'substantial discount' before investment becomes compelling; examples include high-quality firms in retail & food service, software & hardware, and energy. 01 Healthcare Healthcare’s most intriguing feature is that consumers do not interact directly with pharmaceutical or device companies; instead, physicians act as intermediaries making treatment decisions on their behalf. As a result, pricing remains opaque, and individual patients possess little leverage to control costs. This is an inherently attractive sector. The author favors competitive pharmaceutical and medical device companies—but urges greater caution (and wider safety margins) when evaluating biotech firms. 1) Sector Characteristics A defensive industry: demand remains stable across economic cycles—even during deep recessions, people still fall ill and seek care. High profitability, high return on equity (ROE), and abundant free cash flow. Broad scope, numerous sub-sectors, and dynamic evolution. 2) Classification Pharmaceutical Companies (Innovative Drugs): Drug development entails enormous R&D costs and lengthy timelines; newly approved drugs enjoy 20-year patent protection. Once launched, they often generate sustained, high-margin cash flows—single-drug sales frequently exceed $1 billion annually. Pharmaceutical Companies (Generic Drugs): Low manufacturing costs, decent gross margins, rapid market growth, and alignment with government cost-containment policies. Biotechnology Companies: An emerging, innovation-driven field offering faster growth—but also higher risk due to massive R&D expenditures and significant uncertainty in clinical outcomes. Medical Device Companies: Relatively straightforward businesses; product evolution tends toward incremental improvement rather than radical disruption—lower market risk. Economies of scale, high switching costs, and extensive clinical track records collectively form natural barriers to entry. 3) Competitive Advantages Companies in this sector often benefit from several structural advantages: High barriers to entry: e.g., massive R&D outlays, long clinical histories, high physician switching costs, and tightly knit physician networks. Patent protection: 20-year exclusivity for new drugs, typically yielding over a decade of profitable commercialization post-approval. Distinctive products and economies of scale. 4) Key Considerations For R&D-intensive firms, ensure sufficient cash reserves.

Morningstar’s Q4 Outlook: Asian Market Valuations Nearly Fully Adjusted—Three High-Value Sectors Worthy of Increased Allocation

China Securities Journal Editorial Department | Li Jian On the morning of October 20, Morningstar—the world’s leading independent rating agency—held its Q4 Market Outlook Conference. Chen Lizi, Director of Morningstar Asia Equity Research, stated that many high-quality enterprises currently offer excellent value. During the conference, Morningstar’s equity research analysts highlighted three sectors offering superior risk-adjusted value—and published a list of leading companies within them. In Q3, the Morningstar Asia Equity Index declined by 10.3%. Among Asian markets, Japan performed relatively well, while A-shares and Hong Kong stocks lagged significantly. Looking ahead to Q4, Hu Qitai, Senior Equity Analyst at Morningstar, noted: “As of end-September, the average price-to-fair-value ratio across Asian equities stood at 0.72x—suggesting downside risks have been largely priced in. Nevertheless, given various lingering uncertainties, we anticipate continued volatility in the near term.” “For investors with a three-year horizon, numerous high-quality stocks now trade at highly attractive valuations,” Hu advised selectively increasing allocations to quality names that have experienced sharp corrections. “We expect concerns about further interest-rate hikes to ease by end-Q1 2023, lifting investor risk appetite and gradually drawing capital back into equities.” Cyclical Firms to Benefit First from Economic Recovery Alibaba, China Merchants Bank, and DBS Group Highlighted Given persistent macroeconomic headwinds, Hu observed encouraging micro-level improvements in select sectors—creating timely allocation opportunities, which he grouped into three categories. First, cyclical firms. Although Chinese companies in some cyclical sectors faced pandemic-related disruptions this year, government efforts to alleviate logistics bottlenecks and production constraints are gaining traction. Hu expects e-commerce transaction volumes to rebound steadily—a clear tailwind for Alibaba. Over the past year, Alibaba’s share price has weakened amid sluggish macro conditions, pandemic impacts, and intensifying competition from Pinduoduo and short-video platforms in e-commerce. Su Ruzhe, Senior Equity Analyst at Morningstar, commented: “Even if Alibaba’s (e-commerce) market share falls below 50% by 2031, its ‘wide-moat’ brand valuation remains compelling. In our view, these concerns are already fully reflected in its fiscal 2023 forward P/E of just 10.5x.” Su added: “We remain bullish on Alibaba, given its community group-buying initiative Taocai Cai and the expected narrowing losses at its core Taobao platform. We forecast adjusted EBITA for Q3 will rebound from year-on-year decline to flat or positive growth. Government stimulus measures improving macro conditions should further boost Alibaba’s performance in H2 2022—and its 2023 results look promising. Expanded share buybacks will also support the stock price. Recent news signaling regulatory easing has likewise buoyed sentiment.” Additionally, Hu expects financial and real estate sectors to benefit from broader economic recovery—including DBS Group and CapitaLand Integrated Commercial Trust (see Table 1). Hu identified China Merchants Bank (H-share) as his top pick among Chinese banks.

Morningstar Releases Q4 2026 Sector Outlooks and Top Stock Picks

1 day ago

Morningstar analysts released Q4 2026 sector outlooks, identifying undervalued opportunities in basic materials and healthcare while noting financial services as overvalued.

Morningstar

2026-10-13

Morningstar Releases Q4 2026 Sector Outlooks and Top Stock Picks

Morningstar Releases Q4 2026 Sector Outlooks and Top Stock Picks

FAQ